A pilot trial of chemohormonal therapy for metastatic prostate carcinoma

Nancy A. Dawson, George Wilding, Raymond B. Weiss, David G. McLeod, W. Marston Linehan, Joseph A. Frank, Joan L. Jacob, Edward P. Gelmann

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Fifteen patients with previously untreated metastatic prostate cancer were treated on a pilot trial with a combination of maximal androgen blockade plus intermittent cytotoxic therapy after androgen priming to stimulate cell division. Androgen blockage was carried out using a gonadotropin‐releasing hormone analog (leuprolide) plus a nonsteroidal antiandrogen (flutamide). Carboplatin (CBDCA) (800 mg/m2) was given intravenously every 28 days, preceded for 3 days and followed for 3 days by androgen treatment with fluoxymesterone (5 mg orally twice a day), during which time flutamide was discontinued. Three patients (20%) achieved a complete response (CR), and eight patients (53.3%) achieved a partial response (PR). Four patients (26.7%) had stable disease (SD). The median progression‐free survival (PFS) time was 31 months. Nine of 15 patients (60%) remain alive with a median follow‐up time of 42+ months (range, 22 to 54 months). Grade 4 thrombocytopenia and Grades 3 or 4 leukopenia were experienced in 87% and 80% of patients, respectively, requiring dose reductions of CBDCA in 85% of the cycles. Six of 15 patients experienced a flare in bone pain with androgen priming. There were no associated spinal cord compressions; however, exclusion of impending spinal cord compression was required before entrance on study.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
Issue number1
StatePublished - Jan 1 1992
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A pilot trial of chemohormonal therapy for metastatic prostate carcinoma'. Together they form a unique fingerprint.

Cite this